

COVID-19

COVID-19 vaccines: authorised

Table of contents

- [Authorised COVID-19 vaccines](#)
- [Safety updates for authorised COVID-19 vaccines](#)
- [Increasing manufacturing capacity](#)

Vaccines authorised in the European Union (EU) to prevent COVID-19, following evaluation by the European Medicines Agency (EMA).

EMA is not involved in advising on **travel requirements** in the EU, such as vaccination, quarantine or testing for travellers.

Decisions about which COVID-19 vaccines are included, for example, in the **EU Digital COVID Certificate**, are taken by the EU Member States. EMA is in charge of the scientific evaluation of vaccines for EU marketing authorisation. The acceptability criteria for travel purposes are broader and can include, for example, World Health Organization (WHO) listed vaccines that have not necessarily undergone the EMA process of authorisation.

Official information on this topic is available in all EU languages at:

- [Re-open EU website and mobile app](#) 
- [EU Digital Covid Certificate](#) 

Authorised COVID-19 vaccines

The following **vaccines** can be used in the EU to prevent COVID-19:

Show entries

Search:

Vaccine 

Marketing authorisation holder

Key milestones

More information

Comirnaty

BioNTech Manufacturing GmbH

Conditional marketing authorisation issued: 21/12/2020

Annual renewal issued: 03/11/2021

[Latest news](#)

[Safety updates](#)

[Clinical data](#) [🔗](#) (login required)

[Paediatric investigation plan](#)

COVID-19 Vaccine Janssen

Janssen-Cilag International NV

Conditional marketing authorisation issued: 11/03/2021

Annual renewal application: under evaluation

[Latest news](#)

[Safety updates](#)

[Clinical data](#) [🔗](#) (login required)

[Paediatric investigation plan](#)

Spikevax (previously COVID-19 Vaccine Moderna)

Moderna Biotech Spain S.L.

Conditional marketing authorisation issued: 06/01/2021

Annual renewal issued: 04/10/2021

[Latest news](#)

[Safety updates](#)

[Clinical data](#) [🔗](#) (login required)

[Paediatric investigation plan](#)

[Vaxzevria \(previously COVID-19 Vaccine AstraZeneca\)](#)

AstraZeneca AB

Conditional marketing authorisation issued: 29/01/2021

Annual renewal issued: 09/11/2021

[Latest news](#)

[Safety updates](#)

[Clinical data](#) [🔗](#) (login required)

[Paediatric investigation plan](#)

Showing 1 to 4 of 4 entries

Previous

1

Next

For more information on how EMA evaluated these **vaccines**, see:

- [COVID-19 vaccines: Scientific evaluation and approval](#)

Safety updates for authorised COVID-19 vaccines

EMA monitors the safety of COVID-19 vaccines authorised in the EU extremely carefully. This enables the detection of any **rare side effects** that may emerge once many millions of people are vaccinated.

Safety updates on each COVID-19 vaccine are available: